Current and Emerging Targets in Immunotherapy for Osteosarcoma

被引:84
|
作者
Miwa, Shinji [1 ]
Shirai, Toshiharu [1 ,2 ]
Yamamoto, Norio [1 ]
Hayashi, Katsuhiro [1 ]
Takeuchi, Akihiko [1 ]
Igarashi, Kentaro [1 ]
Tsuchiya, Hiroyuki [1 ]
机构
[1] Kanazawa Univ, Sch Med, Dept Orthopaed Surg, Kanazawa, Ishikawa 9208640, Japan
[2] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kyoto 6028566, Japan
关键词
SOFT-TISSUE SARCOMA; LIPOSOMAL MURAMYL TRIPEPTIDE; AUTOLOGOUS TUMOR LYSATE; HIGH-GRADE OSTEOSARCOMA; PULSED DENDRITIC CELLS; DEATH LIGAND 1; T-CELLS; INTRAVENOUS-INJECTION; MONOCYTE ACTIVATION; REFRACTORY BONE;
D O I
10.1155/2019/7035045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
    Hattinger, Claudia Maria
    Patrizio, Maria Pia
    Fantoni, Leonardo
    Casotti, Chiara
    Riganti, Chiara
    Serra, Massimo
    CANCERS, 2021, 13 (12)
  • [22] ESMO Openspecial series on new emerging targets in cancer immunotherapy
    Lambertini, Matteo
    ESMO OPEN, 2019, 4
  • [23] Current therapies and emerging targets for the treatment of diabetes
    Wagman, AS
    Nuss, JM
    CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (06) : 417 - 450
  • [24] Toxoplasmosis: Current and Emerging Parasite Druggable Targets
    Hajj, Rana El
    Tawk, Lina
    Itani, Shaymaa
    Hamie, Maguy
    Ezzeddine, Jana
    El Sabban, Marwan
    El Hajj, Hiba
    MICROORGANISMS, 2021, 9 (12)
  • [25] Erratum: Current and emerging therapeutic targets for IBD
    Markus Neurath
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 688 - 688
  • [26] Current and emerging targets to treat neuropathic pain
    Butera, John A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (11) : 2543 - 2546
  • [27] Immunotherapy for osteosarcoma
    Yahiro, Kenichiro
    Matsumoto, Yoshihiro
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (05) : 1294 - 1295
  • [28] Cross-presented serine proteases as immunotherapy targets for lung cancer and osteosarcoma
    Gibson, Amber
    Sukhumalchandra, Pariya
    Kerros, Celine
    Qiao, Na
    Philips, Anne
    Zhang, Mao
    Alkoutami, Sami
    Semelsberger, Scott
    Lu, Yoshimi
    Byers, Lauren
    Tian, Ze
    Shi, Chunhua
    Yan, Jun
    Zha, Dongxing
    Marinos, Alejandro
    Sergeeva, Anne
    He, Hong
    John, Lisa St.
    Molldrem, Jeffrey J.
    Alatrash, Gheath
    CANCER RESEARCH, 2023, 83 (07)
  • [29] Evaluation of Casncer-testis Antigens in Osteosarcoma and Dedifferntiated Liposarcoma as Targets for immunotherapy
    Jirovec, Anna
    Flaman, Ashley
    Purgina, Bibianna
    Werier, Joel
    Diallo, Jean-Simon
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [30] Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy
    Zhu, Jianshu
    Fan, Jiawei
    Xia, Yuanliang
    Wang, Hengyi
    Li, Yuehong
    Feng, Zijia
    Fu, Changfeng
    FRONTIERS IN PHARMACOLOGY, 2023, 14